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Available online 11 February 2016The Genea096 human embryonic stem cell line was derived from a donated, fully commercially consented ART
blastocyst, carrying a deletion in 4q35 with only 6 D4Z4 repeats by PGD linkage analysis, indicative of FSHD1.
Following ICM outgrowth on inactivated human feeders, karyotype was conﬁrmed as 46, XX by CGH and STR
analysis demonstrated a female Allele pattern. The hESC line had pluripotent cell morphology, 64% of cells
expressed Nanog, 93% Oct4, 58% Tra1-60 and 93% SSEA4 and a Pluritest Pluripotency score of 39.41, Novelty of
1.25. The cell line was negative for Mycoplasma and visible contamination.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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Cell line derivation
The zona pellucida of a blastocyst-stage human embryo was manu-
ally removed using a small blade. The embryo was plated whole onto
irradiated human feeders (Detroit 551 HFF - 90,000/well in 4-well)
in 20% KSR medium with 20 ng/mL FGF added fresh (Amit et al.,
2000). CGH karyotyping and STR proﬁling were performed at the ﬁrst
cryobanking step from ICM outgrowths maintained on feeders. Cells
were then enzymatically passaged as single cells in M2 pluripotent
cell maintenance medium (Genea Biocells) and CGH/karyotyping
repeated, immunoﬂuorescent pluripotent marker staining, pluritest
and sterility testing performed.Genetic analysis
1. Comparative genomic hybridisation (CGH) based chromosomal
analysis: Passage 4; CGH was used to screen targeted regions of
the genome for gains and losses associated with chromosomal
imbalances such as aneuploidy, deletions and duplications. CGH
was performed using SurePrint G3 microarrays (8 × 60 K format)
which were scanned with the Agilent Scanner C and analysedse (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
CGH analysis summary; Genea096 (passage 4) reporting a female cell line and no abnor-
malities detected.
CGH summary
Sample name Genea096p4
Date reported 3rd December 2012
Hybridisation
balance
Balanced hybridization was observed for all chromosomes,
relative to reference DNA
Copy number change No copy number changes N 400 kb were detected
Interpretation Female cell line – no abnormalities detected
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Technologies).
2. DNA proﬁling: Passage 4; DNA ‘ﬁngerprinting’ was performed
using the AmpFLSTR Identiﬁler PCR Ampliﬁcation Kit (Applied
Biosystems #4322288) to provide permanent genetic identiﬁca-
tion of the cell lines. https://www.thermoﬁsher.com/order/catalog/
product/4322288
Pluripotency assessment
1. Immunoﬂuorescence: Passage 8 (6 on feeders, 2 enzymatic); cells
were ﬁxed with formalin and stained with Nanog #560483 1:200;
Oct4 #560217 1:150: Tra1-60 #560121 1:150; SSEA4 #560308
1:200 (all BD Pharmingen). Images were acquired with an IN Cell
Analyser 6000 and quantiﬁed using In Cell Developer Software (GE).
2. Pluritest: Passage 8 (6 on feeders, 2 enzymatic); RNA was collected
and subjected to a Pluritest, a bioinformatic assay of pluripotency in
human cells based on gene expression proﬁles (Müller et al., 2012).Table 2
STR proﬁle; Genea096 (passage 4) demonstrating female allele pattern.
D8S1179 D21S11 D7S820 CSF1PO D3S1358 TH01 D13S31
Genea096p4 10,11 30,32.2 10 10,12 15,16 8,9.3 12,13
Fig. 1. Pluripotency validation of Genea096. A) Immunoﬂuorescent staining (10×) of plur
(passage 8, 2 enzymatic). B) Quantitation of expression of pluripotent markers. C) PluriTes
outlined in black.Sterility testing
1. Mycoplasma: Passage 8 (5 on feeders, 3 enzymatic); testing was
performed as per manufacturer's instructions using the MycoAlert
Mycoplasma Detection Kit from LONZA.
2. Microbial contamination: testingwas performed in conjunctionwith
our QC measures. Cells were thawed and cultured in 7 mL antibiotic
free medium (Genea Biocells M2 medium) for 2–3 days at 37 °C. A
clear solution at ~48–72 h indicated lack of bacterial, fungal or
yeast contamination. Clarity of the solution was assessed by Cell
Production Team.
Veriﬁcation and authentication
Ethics/consents
Ethics approval for the project (‘Derivation of human embryonic
stem cells from embryos identiﬁed through pre-implantation genetic
diagnosis to be affected by known genetic conditions’) was obtained
from the Genea Ethics Committee on 13 September 2005. Excess ART
embryoswere fully consented for stem cell derivation by all responsible
people through an informed consent process (signed de-identiﬁed
consent form can be provided upon request). Donors have received no
payment or ﬁnancial beneﬁts for their donation. Genea096 has been de-
rived from a donated, fully commercially consented embryo, originally
created by assisted reproduction technology (ART) for the purpose
of procreation. The embryo was identiﬁed through pre-implantation
genetic diagnosis to be affected by a genetic mutation andwas declared
excess to reproductive needs. Derivation was performed under
Australian National Health and Medical Research Council (NHMRC)
licence 309710. This licence was issued to GENEA on 7 May 2007.
More information about the licence can be obtained from the NHMRC7 D16S539 D2S1338 D19S433 vWA TPOX D18S51 D5S818 FGA
11 17,23 13,15 16,18 8 14,16 11 22
ipotent cell markers SSEA4 (green), Nanog (red), Oct3/4 (green) and Tra1/60 (red),
t pluripotency (left) and novelty (right) scores with Genea096 (passage 8, 2 enzymatic)
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and-cloning/database-licences-authorising-use-excess-art-embryos
PGD analysis conclusion
Mutation; deletion is 4q35 in the D4Z4 DNA region. Family tree;
Father. Number of D4Z4 repeats is 6. Fascio-Scapulo-Humeral-Muscular
Dystrophy 1 (FSHD1) affected.
Morphology
The derived stem cell line, Genea096, morphologically displays
adherent monolayer of compact cells in well-deﬁned colonies with
high nuclear to cytoplasmic ratio and prominent nucleoli.
Genetic analysis
The cell line has been karyotyped by CGH (Table 1, Supplementary
Fig. 1), demonstrating 46, XX, consistent with original derivation and
pre-implantation genetic diagnosis (PGD). Analysis of STR markers
showed Allele pattern consistent with female genotype (Table 2,
Supplementary Fig. 2).
Pluripotency
GENEA096 is pluripotent by;
1. Immunoﬂuorescence with 64% Nanog positive, 93% Oct4 positive,
58% Tra1-60 positive and 93% SSEA4 positive (Fig. 1A, quantiﬁed
in 1B).
2. Pluritest with a pluripotency score of 39.41 and novelty score of 1.25
(Fig. 1C).Sterility
The cell line is tested and found negative for Mycoplasma and any
visible contamination (Supplementary Fig. 3).
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.scr.2016.02.001.References
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